Chengjiang Zhao
Research Subjects
Chengjiang Zhao has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- David Kempton Cartwright Cooper
Center for Transplantation Sciences Department of Surgery Massachusetts General Hospital/Harvard Medical School Boston Massachusetts USA
3 shared publications Yifan Dai
Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China
3 shared publicationsZhiming Cai
Shenzhen Xenotransplantation Research and Development Center, Institute of Translational Medicine, Shenzhen University Health Science Center, Shenzhen University School of Medicine, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, China
3 shared publicationsHidetaka Hara
2 shared publications- Lisha Mou
Shenzhen Second People's Hospital
2 shared publications Changyou Wu
Institute of Immunology, Zhongshan School of Medicine, Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, Sun Yat-Sen University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 31 July 2026
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (4) , e70308
Potent and Sustained Lowering of Serum Uric Acid by YJH ‐012‐D, a G al NA c‐Conjugated si RNA Targeting Xanthine Dehydrogenase
Hyperuricemia (HUA) is primarily driven by hepatic overproduction of urate, mediated by xanthine dehydrogenase (XDH). This preclinical study evaluates YJH‐012‐D, a N ‐acetylgalactosamine (GalNAc)‐conjugated small interfering RNA (siRNA) targeting hepatic XDH . Functional assays demonstrated that YJH‐012‐D potently suppressed both XDH mRNA and protein expression in primary hepatocytes. In mice, a single subcutaneous dose of 8 mg/kg significantly reduced serum uric acid levels and suppressed hepatic XDH expression for more than 42 days. In cynomolgus monkeys, administration of YJH‐012‐D at 10 mg/kg lowered serum uric acid for up to 180 days, with sustained XDH inhibition observed for 120 days. Pharmacokinetic analysis revealed a high liver‐to‐plasma area under the curve (AUC) ratio (2000–6100) and a hepatic half‐life exceeding 10 days, consistent with prolonged pharmacological activity. Comprehensive toxicity assessments—including clinical biochemistry, histopathology, and RNA sequencing (RNA‐seq)‐based off‐target profiling—identified no significant adverse effects. Collectively, YJH‐012‐D exhibits potent, durable urate‐lowering efficacy and a favorable safety profile, underscoring its potential as a novel therapeutic candidate for HUA.
- 31 July 2026
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (4) , e70308
Open AccessPotent and Sustained Lowering of Serum Uric Acid by YJH ‐012‐D, a G al NA c‐Conjugated si RNA Targeting Xanthine Dehydrogenase
Hyperuricemia (HUA) is primarily driven by hepatic overproduction of urate, mediated by xanthine dehydrogenase (XDH). This preclinical study evaluates YJH‐012‐D, a N ‐acetylgalactosamine (GalNAc)‐conjugated small interfering RNA (siRNA) targeting hepatic XDH . Functional assays demonstrated that YJH‐012‐D potently suppressed both XDH mRNA and protein expression in primary hepatocytes. In mice, a single subcutaneous dose of 8 mg/kg significantly reduced serum uric acid levels and suppressed hepatic XDH expression for more than 42 days. In cynomolgus monkeys, administration of YJH‐012‐D at 10 mg/kg lowered serum uric acid for up to 180 days, with sustained XDH inhibition observed for 120 days. Pharmacokinetic analysis revealed a high liver‐to‐plasma area under the curve (AUC) ratio (2000–6100) and a hepatic half‐life exceeding 10 days, consistent with prolonged pharmacological activity. Comprehensive toxicity assessments—including clinical biochemistry, histopathology, and RNA sequencing (RNA‐seq)‐based off‐target profiling—identified no significant adverse effects. Collectively, YJH‐012‐D exhibits potent, durable urate‐lowering efficacy and a favorable safety profile, underscoring its potential as a novel therapeutic candidate for HUA.
- 1 June 2019
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 514 (1) , 92-97
Oleate inhibits hepatic autophagy through p38 mitogen-activated protein kinase (MAPK)
- 1 June 2019
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 514 (1) , 92-97
Oleate inhibits hepatic autophagy through p38 mitogen-activated protein kinase (MAPK)
- 11 May 2019
- Published by Wiley in Xenotransplantation
- Vol. 26 (4) , e12522
Circulating pig‐specific DNA as a novel biomarker for monitoring xenograft rejection
Monitoring for immune rejection is crucial for long‐term survival of pig xenografts. Circulating DNA is a promising non‐invasive biomarker for either organ injury or response to therapy. In this study, circulating pig‐specific DNA (cpsDNA) was monitored during xenograft rejection. Potential targets of cpsDNA were selected by in silico analysis, and species specificity of selected primers was confirmed by PCR. Subsequently, cpsDNA as a biomarker was evaluated using a complement‐dependent cytotoxicity (CDC) assay in vitro. Then, early diagnosis and response to rapamycin were assessed by an in vivo imaging model of pig‐to‐mouse cell transplantation. Finally, cpsDNA was monitored in a pig‐to‐monkey artery patch transplantation model. The results showed that (a) a method of cpsDNA quantitation was established for application in mouse and nonhuman primate models; (b) cpsDNA reflected CDC in vitro; (c) cpsDNA in vivo mirrored xenograft rejection, and correlated with xenograft loss in pig‐to‐mouse cell transplantation; (d) cpsDNA was significantly reduced when rapamycin was administered; and (e) dynamic cpsDNA was detectable in pig‐to‐monkey artery patch transplantation. In conclusion, measurement of cpsDNA could prove to be a less invasive, but more specific and sensitive low‐cost biomarker enabling monitoring of xenograft rejection and the response to immunosuppressive therapy.
- 11 May 2019
- Published by Wiley in Xenotransplantation
- Vol. 26 (4) , e12522
Circulating pig‐specific DNA as a novel biomarker for monitoring xenograft rejection
Monitoring for immune rejection is crucial for long‐term survival of pig xenografts. Circulating DNA is a promising non‐invasive biomarker for either organ injury or response to therapy. In this study, circulating pig‐specific DNA (cpsDNA) was monitored during xenograft rejection. Potential targets of cpsDNA were selected by in silico analysis, and species specificity of selected primers was confirmed by PCR. Subsequently, cpsDNA as a biomarker was evaluated using a complement‐dependent cytotoxicity (CDC) assay in vitro. Then, early diagnosis and response to rapamycin were assessed by an in vivo imaging model of pig‐to‐mouse cell transplantation. Finally, cpsDNA was monitored in a pig‐to‐monkey artery patch transplantation model. The results showed that (a) a method of cpsDNA quantitation was established for application in mouse and nonhuman primate models; (b) cpsDNA reflected CDC in vitro; (c) cpsDNA in vivo mirrored xenograft rejection, and correlated with xenograft loss in pig‐to‐mouse cell transplantation; (d) cpsDNA was significantly reduced when rapamycin was administered; and (e) dynamic cpsDNA was detectable in pig‐to‐monkey artery patch transplantation. In conclusion, measurement of cpsDNA could prove to be a less invasive, but more specific and sensitive low‐cost biomarker enabling monitoring of xenograft rejection and the response to immunosuppressive therapy.
- 1 March 2018
- Published by Wiley in Xenotransplantation
- Vol. 25 (2)
Cover Image, Volume 25, Issue 2
- 11 February 2018
- Published by Wiley in Xenotransplantation
- Vol. 25 (2) , e12386
The Sda and Cad glycan antigens and their glycosyltransferase, β1,4GalNAcT‐II, in xenotransplantation
Antibody‐mediated rejection is a barrier to the clinical application of xenotransplantation, and xenoantigens play an important role in this process. Early research suggested that N‐acetyl‐D‐galactosamine (GalNAc) could serve as a potential xenoantigen. GalNAc is the immunodominant glycan of the Sda antigen. Recently, knockout of β1,4‐N‐acetylgalactosaminyltransferase 2 (β1,4GalNAcT‐II) from the pig results in a decrease in binding of human serum antibodies to pig cells. It is believed that this is the result of the elimination of the GalNAc on the Sda antigen, which is catalyzed by the enzyme, β1,4GalNAcT‐II. However, research into human blood group antigens suggests that only a small percentage (1%‐2%) of people express anti‐Sda antibodies directed to Sda antigen, and yet a majority appear to have antibodies directed to the products of pig B4GALNT2. Questions can therefore be asked as to (i) whether the comprehensive structure of the Sda antigen in humans, that is, the underlying sugar structure, is identical to the Sda antigen in pigs, (ii) whether the human anti‐Sda antibody binds ubiquitously to pig cells, but not to human cells, and (iii) what role the Sda++ (also called Cad) antigen is playing in this discrepancy. We review what is known about these antigens and discuss the discrepancies that have been noted above.
- 11 February 2018
- Published by Wiley in Xenotransplantation
- Vol. 25 (2) , e12386
The Sda and Cad glycan antigens and their glycosyltransferase, β1,4GalNAcT‐II, in xenotransplantation
Antibody‐mediated rejection is a barrier to the clinical application of xenotransplantation, and xenoantigens play an important role in this process. Early research suggested that N‐acetyl‐D‐galactosamine (GalNAc) could serve as a potential xenoantigen. GalNAc is the immunodominant glycan of the Sda antigen. Recently, knockout of β1,4‐N‐acetylgalactosaminyltransferase 2 (β1,4GalNAcT‐II) from the pig results in a decrease in binding of human serum antibodies to pig cells. It is believed that this is the result of the elimination of the GalNAc on the Sda antigen, which is catalyzed by the enzyme, β1,4GalNAcT‐II. However, research into human blood group antigens suggests that only a small percentage (1%‐2%) of people express anti‐Sda antibodies directed to Sda antigen, and yet a majority appear to have antibodies directed to the products of pig B4GALNT2. Questions can therefore be asked as to (i) whether the comprehensive structure of the Sda antigen in humans, that is, the underlying sugar structure, is identical to the Sda antigen in pigs, (ii) whether the human anti‐Sda antibody binds ubiquitously to pig cells, but not to human cells, and (iii) what role the Sda++ (also called Cad) antigen is playing in this discrepancy. We review what is known about these antigens and discuss the discrepancies that have been noted above.